Product logins

Find logins to all Clarivate products below.


Dee Chaudhary

Director, Consulting

With more than 25 years in life sciences and a passion for patients, Dee Chaudhary is a Director with Clarivate’s Commercial Strategy Consulting practice.  Her work in consulting, and within the biopharmaceutical industry has primarily focused on HUB/patient services, launch readiness, CMS policy impact, customer experience and market access strategy in the hematology and oncology space.

Dee has extensive professional experience with 340B pricing, reimbursement strategy, product positioning and value propositions for oral and infusible agents.  She has led HUB migrations, benchmarking engagements, customer satisfaction projects, omni-channel projects, product differentiation, pricing and positioning efforts, and payer landscape analysis.  Furthermore, Dee has an in-depth understanding of the hematology and oncology market landscape, targeted and cellular therapies, and has a strong interest and experience in other therapeutic areas including cardiology, neuroscience, med tech immunotherapy, and using technology to advance health and access. She has been invited to presented at Asembia, ISPOR and other clinical meetings, and has authored multiple trainings and white papers.

Prior to joining Clarivate, Dee held a variety roles at small and large biopharmaceutical organizations and consulting firms, including National Director of Market Access, Reimbursement and Trade, Senior Director of Customer Experience, and Assistant Director of Reimbursement Consulting. Dee holds a BA from Gustavus Adolphus College in History, and an MBA in Healthcare Administration.


arrow_forward
Get in touch with Dee

Related resources

为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇 为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇
Blog March 2, 2026
为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇
AI/机器学习 GLP-1 临床试验 交易 药政法规 衰老生物学
为何更方便的给药方式并未获得支付方青睐 为何更方便的给药方式并未获得支付方青睐
Blog February 26, 2026
为何更方便的给药方式并未获得支付方青睐
医疗保险 定价 市场准入 真实世界数据 美国市场
应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径 应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
Blog February 24, 2026
应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
前进之路:收到 CRL 后该何去何从? 前进之路:收到 CRL 后该何去何从?
Blog February 24, 2026
前进之路:收到 CRL 后该何去何从?
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规